TY - JOUR T1 - Healthcare utilisation and costs in the diagnosis and treatment of progressive-fibrosing interstitial lung diseases JF - European Respiratory Review JO - EUROPEAN RESPIRATORY REVIEW DO - 10.1183/16000617.0078-2018 VL - 27 IS - 150 SP - 180078 AU - Colin Holtze AU - Kevin Flaherty AU - Michael Kreuter AU - Fabrizio Luppi AU - Teng Moua AU - Carlo Vancheri AU - Mary B. Scholand Y1 - 2018/12/31 UR - http://err.ersjournals.com/content/27/150/180078.abstract N2 - There are over 200 interstitial lung diseases (ILDs). In addition to patients with idiopathic pulmonary fibrosis (IPF), a percentage of patients with other ILDs also develop progressive fibrosis of the lung during their disease course. Patients with progressive-fibrosing ILDs may show limited response to immunomodulatory therapy, worsening symptoms and lung function and, ultimately, early mortality. There are few data for ILDs that may present a progressive fibrosing phenotype specifically, but we believe the burden and healthcare costs associated with these conditions may be comparable to those reported in IPF. This review discusses the burden of ILDs that may present a progressive fibrosing phenotype and the factors impacting healthcare utilisation.Data for ILDs with a progressive fibrosing phenotype are lacking, but the burden and healthcare costs associated with these conditions may be comparable to those reported in IPF http://ow.ly/Eoht30mS4Nx ER -